Rozanolixizumab Biosimilar - Research Grade

Human

FcRn

>1mg/ml

Human IgG4-Lambda2

Batoclimab Biosimilar - Research Grade (ICH5049), Nipocalimab Biosimilar - Research Grade (ICH5050), Efgartigimod Biosimilar - Research Grade (ICH5223), Orilanolimab Biosimilar - Research Grade (ICH5744)

https://www.imgt.org/mAb-DB/

ICH3002

P55899

2217

RRID:AB_2921593

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of rozanolixizumab, supplied strictly for research use only (not for human or veterinary use). Rozanolixizumab is a humanized IgG4 monoclonal antibody that binds the neonatal Fc receptor (FcRn) and blocks its interaction with the Fc region of IgG, thereby accelerating the degradation of circulating IgG including pathogenic autoantibodies. The research-grade analog reproduces the binding specificity of the originator against human FcRn, making it a useful tool for interrogating FcRn biology, antibody recycling, and IgG homeostasis in vitro and in preclinical systems. Typical applications include use as a reference or positive-control anti-FcRn binder in receptor-binding and blocking assays, as a benchmarking reagent in FcRn-dependent transcytosis and recycling studies, and as a comparator in biosimilarity or assay-development workflows. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities for scale-dependent experiments. It is an analog built around the FcRn target, not the clinical drug. FcRn, the neonatal Fc receptor, is encoded by FCGRT (UniProt P55899) and functions as a heterodimer of an MHC class I-like alpha chain paired with beta-2-microglobulin. Unlike classical Fc-gamma receptors, FcRn binds the Fc region of IgG in a strictly pH-dependent manner: it engages IgG in acidified early endosomes (pH ~6.0) after fluid-phase uptake, then releases it at neutral extracellular pH (~7.4). This cycle rescues internalized IgG and albumin from lysosomal degradation and recycles them back to the circulation, giving IgG its characteristically long serum half-life and maintaining IgG and albumin homeostasis. FcRn also mediates transcytosis of IgG across epithelial and endothelial barriers, including maternal-fetal transfer. Blocking FcRn shortens IgG half-life and lowers total IgG, the rationale behind therapeutic FcRn antagonism in IgG-mediated autoimmune disease.

IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, IgG receptor FcRn large subunit p51, FCGRT

Detects human FcRn. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rozanolixizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Rozanolixizumab (anti-FcRn) Biosimilar

Q: Is the Rozanolixizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Rozanolixizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Rozanolixizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Rozanolixizumab that binds human FcRn.